Format

Send to

Choose Destination
Urol Clin North Am. 2015 Aug;42(3):347-57. doi: 10.1016/j.ucl.2015.04.009.

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies.

Author information

1
Division of Medical Oncology, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
2
Division of Medical Oncology, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA. Electronic address: dorff@usc.edu.

Abstract

The rate of diagnosis of germ cell tumors has remained fairly constant. By the International Germ Cell Cancer Consensus Classification, roughly 60% of all metastatic germ cell tumors are classified as good risk. This group of patients has an excellent prognosis, with greater than 90% expectation of cure. Treatment standards have not changed much in recent years. This article focuses on key concepts in the development of the currently accepted first-line regimens and addresses some evolving areas of interest, if not controversy.

KEYWORDS:

Bleomycin; Cisplatin; Etoposide; Germ cell tumor

PMID:
26216822
DOI:
10.1016/j.ucl.2015.04.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center